康诺亚(02162.HK) 公布，其全资附属成都康诺亚与Timberlyne Therapeutics已订立独家对外许可协议，授予目标公司在全球(不包括内地、香港、澳门及台湾)开发、生产及商业化CM313的独家权利。CM313为集团自主研发的靶向CD38的人源化单克隆抗体。
作为回报，集团将收取3,000万美元的首付款和近期付款，并获得目标公司25.79%的股权，成为其最大股东。在达成若干销售及开发里程碑后，集团亦可收取最多3.38亿美元的额外付款。集团亦有权从目标公司收取销售净额的分层特许权使用费。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-09 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.